Cardiometabolic disease, a term encompassing a cluster of conditions that increase the risk of cardiovascular disease and metabolic disorders, represents a significant health challenge in today's society. This multifaceted group includes conditions such as obesity, type 2 diabetes, and hypertension, which collectively contribute to an elevated risk of heart disease and stroke. The intricate interplay between genetics, lifestyle factors, and environmental influences underscores the complexity of cardiometabolic diseases. Sedentary lifestyles, poor dietary choices, and genetic predispositions can contribute to the development and progression of these interconnected conditions. Early detection and comprehensive management strategies are crucial in mitigating the impact of cardiometabolic disease, emphasizing the importance of lifestyle modifications, medication adherence, and regular health screenings. Public health initiatives aimed at promoting awareness, education, and preventive measures play a pivotal role in addressing the rising prevalence of cardiometabolic disease and fostering a healthier population.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India